Laura Shawver - Dec 2, 2024 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Role
Director
Signature
/s/ Kathleen Scott, Attorney-in-Fact
Stock symbol
SPRY
Transactions as of
Dec 2, 2024
Transactions value $
-$2,289,709
Form type
4
Date filed
12/4/2024, 09:40 PM
Previous filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRY Common Stock Options Exercise $85.9K +67.6K +32.15% $1.27 278K Dec 2, 2024 Direct
transaction SPRY Common Stock Options Exercise $37.6K +29.6K +10.66% $1.27 308K Dec 2, 2024 Direct
transaction SPRY Common Stock Sale -$1.31M -96.3K -31.32% $13.55 211K Dec 2, 2024 Direct F1, F2
transaction SPRY Common Stock Sale -$12.9K -901 -0.43% $14.34 210K Dec 2, 2024 Direct F1, F3
transaction SPRY Common Stock Options Exercise $32.5K +25.6K +12.17% $1.27 236K Dec 3, 2024 Direct
transaction SPRY Common Stock Options Exercise $196K +62.4K +26.44% $3.15 298K Dec 3, 2024 Direct
transaction SPRY Common Stock Sale -$1.17M -88K -29.49% $13.26 210K Dec 3, 2024 Direct F1, F4
transaction SPRY Common Stock Options Exercise $46.5K +14.8K +7.02% $3.15 225K Dec 4, 2024 Direct
transaction SPRY Common Stock Sale -$203K -14.8K -6.56% $13.75 210K Dec 4, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -29.6K -53.64% $0.00 25.6K Dec 2, 2024 Common Stock 29.6K $1.27 Direct F6
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -67.6K -100% $0.00 0 Dec 2, 2024 Common Stock 67.6K $1.27 Direct F6, F7
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -25.6K -100% $0.00 0 Dec 3, 2024 Common Stock 25.6K $1.27 Direct F6
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -62.4K -45.79% $0.00 73.8K Dec 3, 2024 Common Stock 62.4K $3.15 Direct F6
transaction SPRY Stock Option (Right to Buy) Options Exercise $0 -14.8K -20.01% $0.00 59.1K Dec 4, 2024 Common Stock 14.8K $3.15 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024.
F2 The weighted average sale price for the transaction reported was $13.5539 and the range of prices were between $13.27 and $14.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The weighted average sale price for the transaction reported was $14.3417 and the range of prices were between $14.2761 and $14.375. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F4 The weighted average sale price for the transaction reported was $13.2626 and the range of prices were between $12.92 and $13.62. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5 The weighted average sale price for the transaction reported was $13.7496 and the range of prices were between $13.39 and $14.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F6 Immediately exercisable.
F7 Due to a clerical error, the total number of shares subject to this option grant was underreported by one share on the Reporting Person's Form 3 and is corrected on this filing.